Aspira Women`s Health Inc Stock Price, News & Analysis

Aspira Women’s Health Inc. announced the publication of a paper validating its OvaWatch™ algorithm for detecting ovarian cancer in the June issue of JCO Clinical Cancer Informatics. The study highlights OvaWatch's potential in assessing the risk of ovarian malignancy in patients with pelvic masses, essential for early detection of this deadly gynecologic cancer. The company aims to launch OvaWatch as a valuable tool for physicians, potentially improving health outcomes for women. CEO Nicole Sandford expressed optimism about its future impact on treatment strategies.

Aspira Women’s Health Inc. (Nasdaq: AWH) has announced management participation in two upcoming investor conferences. The MicroCap Rodeo Spring Into Action Conference is scheduled for May 17, 2022 at 12:30pm ET, with a webcast available here. The William Blair 42nd Annual Growth Stock Conference will take place on June 7, 2022, at 8:00am CT (9:00am ET), with a webcast accessible here. One-on-one meetings will also be available on June 7-8.

Aspira Women’s Health Inc. (AWH) reported a 30% increase in product revenue to $1.8 million for Q1 2022, driven by a 47% rise in new ordering physicians to 603. OVA1plus tests increased by 28% to 4,819 units. Gross profit margin slightly declined to 53%, and R&D expenses surged by 55%. Despite increased operational expenses, the company ended Q1 with approximately $27.1 million in cash, and plans to launch the OVAWatch test in stages during 2022 and 2023. Leadership changes include the appointment of Dr. Ryan Phan as Chief Operating and Scientific Officer.

Aspira Women’s Health, Inc. (AWH) will release its financial results for Q1 2022 on May 11, 2022, prior to market opening. A conference call is scheduled for 8:30 AM ET to discuss these results and provide a corporate update. Aspira focuses on innovative testing solutions for women’s health, striving to improve gynecologic outcomes, particularly in ovarian cancer risk assessment. The company has launched Aspira Synergy technology to enhance testing accessibility and is developing new diagnostic products.

Aspira Women's Health (AWH) reported a 46% increase in total revenue for 2021, reaching $6.8 million, driven by a 28% growth in OVA1plus test volume to 17,359 units. The company exercised a world-wide license option for cutting-edge miRNA technology in collaboration with Harvard Dana-Farber Cancer Institute. Despite a 153% rise in research and development expenses and a 60% increase in general and administrative costs, the gross profit margin for OVA1plus improved to 55%. Aspira ended the year with $37.42 million in cash and is optimistic about future growth.

Aspira Women’s Health (AWH) will report its financial results for the year ended December 31, 2021, on March 23, 2022, prior to market opening. A conference call with investors is scheduled for 8:30 AM ET on the same day to discuss the results and provide corporate updates. Aspira specializes in innovative women's health solutions, particularly focusing on ovarian cancer risk assessment and pelvic diseases. With over a decade of expertise, they are advancing their portfolio with new products like OVAWatch and EndoCheck, aiming to enhance gynecologic health outcomes.

Aspira Women’s Health (AWH) appointed Celeste Fralick, Ph.D., to its Board of Directors effective February 23, 2022. Dr. Fralick brings over 40 years of data strategy experience, particularly in healthcare and technology. Notable for her leadership roles at McAfee and Intel, she has been recognized by Forbes as one of the Top 50 Women in Technology. The Board's Chair, James LaFrance, and President, Valerie Palmieri, expressed confidence in her capabilities to guide the company’s expanding portfolio and initiatives aimed at enhancing women's health outcomes.

Aspira Women’s Health Inc. (Nasdaq: AWH) announced changes in its leadership team effective March 1, 2022. Valerie Palmieri transitions to Executive Chair of the Board, while Nicole Sandford takes on the role of President and CEO. Jim LaFrance will become Lead Independent Director. Palmieri's tenure as CEO has been marked by significant advancements in women's health diagnostics, particularly in ovarian cancer. Sandford, joining from the Ellig Group, aims to leverage her extensive operational experience to boost product launches and drive growth.

Aspira Women’s Health (Nasdaq: AWH) has appointed Mr. Michael Newton as the new Head of Sales and Marketing, bringing over 20 years of experience in diagnostics to the company. Newton will oversee U.S. commercialization, focusing on driving adoption of the OVA1Plus product for early ovarian cancer risk detection. President and CEO Valerie Palmieri expressed enthusiasm for Newton's strategic expertise in enhancing product adoption and market growth. Aspira aims to solidify its position in gynecologic health with innovative testing solutions and advanced technology transfer.